FELIQS Corporation, a biotechnology firm specializing in innovative treatments for rare pediatric retinal diseases, has announced the completion of a $9 million Series A funding round. This financial boost, co-led by a prominent American pharmaceutical company and Beyond Next Ventures Inc., with contributions from the Japan Science and Technology Agency and existing investors, is set to accelerate the clinical development of FLQ-101. FLQ-101 is FELIQS's lead candidate aimed at preventing retinopathy of prematurity (ROP), a condition that poses a significant risk of blindness in premature infants.
The funding will support the Phase 1b/2 tROPhy-1 study of FLQ-101, scheduled to begin in the summer of 2025 in the United States. FLQ-101, which has received both Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA), represents a novel approach to treating ROP. It is designed as a once-daily oral or intravenous solution that promotes healthy retinal vascularization while combating inflammation and abnormal blood vessel growth.
Dr. Ken-ichiro (Nobu) Kuninobu, Co-Founder and CEO of FELIQS, expressed gratitude for the investment, highlighting its importance in advancing the company's clinical studies and expanding its pipeline of treatments for pediatric patients. The proceeds from this funding round will be utilized to enhance FELIQS's operational and clinical development teams, expedite key milestones in the U.S. clinical program, and foster collaborative research efforts in the United States.
This development underscores the potential of FLQ-101 to address a pressing unmet medical need in the field of neonatal care, offering hope for improved outcomes for premature infants at risk of ROP. The successful funding round not only validates the scientific and therapeutic promise of FELIQS's approach but also sets the stage for significant advancements in the treatment of rare pediatric retinal diseases.
